News | May 18, 2026
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
Medanta expanded its bed capacity by 20% during the year
The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Subscribe To Our Newsletter & Stay Updated
